德勤：中国生命科学与医疗行业调研结果：2023年行业现状与展望报告（中译版）（38页）.pdf

1、China Life Sciences&Health Care TeamMarch 2023China LSHC IndustryChina LSHC IndustrySurvey Result:2023 State of Industry in China2China LSHC Industry 2023 Survey Results 2023.For information,contact Deloitte China.Content Framework Results Questions&Deep-diveWhat happened in 2022What expected in 202

2、3 Concluding insights Appendix3China LSHC Industry 2023 Survey Results 2023.For information,contact Deloitte China.Note:1 SOE:State-owned Enterprise;2 POE:Private-owned Enterprise;3 JV:Joint Venture;4 WOFE:Wholly Foreign-owned Enterprise LSHC Industry 2023 Outlook SurveyFramework3%32%9%56%SOEPOEJVWO

3、FE20%45%35%Chairman/CEOC-suit levelOther management level68%1%22%7%2%PharmaDistributor/RetailerMedical DevicesHealthcare ServicesOther sector15%20%22%43%Less than RMB 100 millionRMB 100 million-1 billionRMB 1 billion-5 billionMore than RMB 5 billionCompany Type56%37%7%Less than 5,0005,000 10,000More

4、 than 10,000Survey conducted between 10thto 23rdJanuary 2023Engaged China based Life Science&Healthcare(LSHC)sector operators and investors:115 respondents Respondents TypeBusiness SectorNo.of Employees2022 Revenue Size4China LSHC Industry 2023 Survey Results 2023.For information,contact Deloitte Ch

5、ina.What happened in 2022 5China LSHC Industry 2023 Survey Results 2023.For information,contact Deloitte China.Note:1 Large cos:enterprise with revenue above RMB 1 billion;2 SOE:State-owned Enterprise;3 POE:Private-owned Enterprise;4 WOFE:Wholly Foreign-owned Enterprise;5 Life Science:Pharma&Medical

6、 Devices 2022 Performance Review Question#1 How did your company perform(top line)in previous year?13%41%46%33%48%19%Annual financial performanceis better than plannedAnnual financial performanceis in line with plansAnnual financial performanceis worse than plans11%37%52%30%45%25%ALLLarge cosSOE&POE